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Abstract
Multi-output Gaussian processes (GPs) are a flexible Bayesian nonparametric
framework that has proven useful in jointly modeling the physiological states of
patients in medical time series data. However, capturing the short-term effects
of drugs and therapeutic interventions on patient physiological state remains chal-
lenging. We propose a novel approach that models the effect of interventions as
a hybrid Gaussian process composed of a GP capturing patient physiology con-
volved with a latent force model capturing effects of treatments on specific phys-
iological features. This convolution of a multi-output GP with a GP including
a causal time-marked kernel leads to a well-characterized model of the patients’
physiological state responding to interventions. We show that our model leads to
analytically tractable cross-covariance functions, allowing scalable inference. Our
hierarchical model includes estimates of patient-specific effects but allows sharing
of support across patients. Our approach achieves competitive predictive perfor-
mance on challenging hospital data, where we recover patient-specific response
to the administration of three common drugs: one antihypertensive drug and two
anticoagulants.
1 Introduction
In the era of digital medicine, modern medical devices enable clinicians to accurately and frequently
measure the physiological state of their patients. Heart rate, blood pressure, arterial oxygen satura-
tion, and white blood cell counts are just a few of the vital signs used to monitor patient state and to
predict outcomes such as hospital discharge rate, patient survival, or readmission (Rajkomar et al.,
2018; Ranganath et al., 2016). To model the complex relationships governing patient state dynam-
ics, a large body of work takes advantage of the flexible properties of Gaussian processes (GPs).
Both single-output (Stegle et al., 2008; Lasko et al., 2013) and multi-output methods (Nemati et al.,
2012; Ghassemi et al., 2015; Cheng et al., 2017; Futoma et al., 2017) use carefully designed kernels
to improve prediction accuracy of patient states across sparse, noisy, and irregularly sampled time
series horizons. These methods predict correlations between patient vital signs that give insight into
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imputing hard-to-sample state variables, detecting patient trends, and making decisions under uncer-
tainty. Modeling patient state dynamics is made difficult by the administration of drugs and other
therapeutic interventions, which directly impact state features for a limited time window and often
return to baseline. Accurate prediction of patient state following an intervention allows a clinician
to consider multiple options for intervention and make informed treatment decisions.
Recent papers have attempted to model the complex effects of interventions on patient state
(Xu et al., 2016; Schulam and Saria, 2017). These models do not incorporate a control systems un-
derstanding of the complex mechanisms governing the tightly controlled responses of physiological
traits to interventions. This leads to inaccurate and non-generalizeable predictions when insuffi-
cient training data is available, which is often the case when predictions include a patient-specific
component.
One motivation for modeling intervention effects on patient state with dynamical systems is to learn
optimal treatment policies. For instance, prior work adapted reinforcement learning (RL) to derive
a closed-loop anesthesia controller to regulate mean arterial pressure based on a dynamical patient
model (Padmanabhan et al., 2015). Other applications, such as finding multi-drug therapies for
human immunodeficiency virus (HIV), have used dynamical systems models (Adams et al., 2004).
In this paper, we introduce a Bayesian nonparametric framework for estimating the dynamics of
clinical traits in response to drug interventions through electronic health records (EHRs) from hos-
pital patients. Specifically, we develop an approach to learn the patient-specific response of clinical
traits to treatments from medical time series data. Our approach consists of a multi-output Gaussian
process (GP) derived from latent force models (LFMs) (Alvarez et al., 2009), which we model using
GPs with kernels derived from differential equations representing dynamical systems. To model the
effect of multiple treatments on patient-specific clinical traits, we use latent force functions sampled
from Gaussian processes with causal kernels. By estimating patient-specific parameters to capture
the effects of treatments on specific clinical traits, our model offers novel mechanistic insights and
achieves competitive predictive accuracy of physiological response to interventions when compared
with state-of-the-art methods (Soleimani et al., 2017).
The contributions of this work are two-fold. First, we compose causal kernels in time-marked med-
ical data to capture the latent dynamics of interventions effects using a GP. Second, we incorporate
these treatment effects in a model of patient state by convolving this causal kernel latent force model
with a multi-output GP that captures patient state absent interventions. Our approach is a necessary
step towards achieving optimal control of patient health through targeted, personalized treatments
(Särkkä et al., 2017). We show the predictive value of our approach on a large hospital data set.
2 Background
2.1 Gaussian Processes for Time Series
In the medical time series setting, data are collected from n patients, indexed by i, across Ti time
points indexed by t. Single output data typically correspond to time-varying covariates encoding
physiological states such as blood pressure or heart rate. The measured pairs D = {xi, yi}ni=1,
where xi corresponds to the time at which the covariate yi ∈ R was recorded, are then modeled
through an underlying latent function f(·) such that yi = f(xi) + ǫi, where ǫi ∼ N (0, σ2i ) is
independent Gaussian noise. The goal is to estimate and to evaluate f(·) at future time points to
enable prediction and early detection of physiologically abnormal states.
Gaussian processes (GPs) represent a versatile generative framework for modeling the distribution
on a real-valued function f(·). GPs are nonparametric stochastic processes specified by mean and
covariance functions:
f(x) ∼ GP(µ(x), k(x,x′)), (1)
where µ(x) is the mean function µ(x) = E[f(x)] and k(x,x′) is the covariance function or kernel:
k(x,x′) = E[(f(x) − µ(x))(f(x′) − µ(x′))]. The mean function µ(x) is often assumed to be
zero (Rasmussen and Williams, 2006). An immediate result is the multivariate Gaussian form of
the joint [f(x1), f(x2), . . . f(xn)] ∼ N (0,K), where K is the n × n kernel matrix with entries
Ki,j = k(xi, xj).
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Properties of the function f(x) such as smoothness or periodicity are determined by the kernel
function k(x,x′). One commonly used kernel is the squared exponential (SE) kernel
k(x,x′) = σ2 exp
(
−||x− x
′||2
2ℓ2
)
, (2)
which is parameterized by a length scale ℓ and a scale factor σ. The functions generated by a GP
with an SE kernel are smooth because the kernel function is infinitely differentiable. SE kernels
capture stationary processes, as the covariance between two vectors depends on the difference in
time (or other covariate) ||x− x′|| but not on absolute time.
GPs have been studied extensively in the context of time series (Roberts et al., 2012), and are espe-
cially useful when the data are sparsely or irregularly sampled. In medical time series, the clinical
measurements are recorded sporadically and sometimes sparsely across time. To better model mul-
tiple correlated measurements, multi-output GPs (MOGPs), which capture the covariance structure
between multiple measurements, have been adapted for use on medical data (Ghassemi et al., 2015;
Futoma et al., 2017; Cheng et al., 2017). However, kernels used to capture temporal dependencies
between sequential clinical measurements are mostly stationary. This is a limitation since, during
a patient’s stay in the hospital, clinical events and interventions occur, and physiological dynamics
often vary across time.
2.2 Latent Force Models for Patient Data
Physiological dynamics have been long studied by physiologists using systems of differential equa-
tions. In the case of heart rate and blood pressure, for example, the cardiac conduction system
is assumed to be a network of self-excitatory pacemakers leading to systems of nonlinear oscilla-
tors (Glass, 2001). Medical time series-based prediction of such covariates has relied on regression
models, linear and nonlinear, including but not limited to GPs; yet an explicit connection with con-
trol theory has been lacking. Recently, several methods were proposed to bridge the gap between
stochastic control methods and nonparametric time series models (Gao et al., 2008; Alvarez et al.,
2009). In particular, multi-output GPs are one approach to representing latent force models, where
the covariance functions (kernels) are derived using ordinary differential equations (ODEs). In the
LFM setup, we would like to model the system dynamics between a set of observed processes,
{gq(t)}Qq=1, and a set of unobserved latent forces, fm(t), assuming that they interact according to
differential equations capturing those dynamics. For example, in a first-order LFM, the following
equation holds:
dgq(t)
dt
+Dqgq(t) = Bq +
M∑
m=1
Sqmfm(t), (3)
with Bq and Dq representing the base level value and underlying decay parameter of each output
q, and Sqm the influence constants from each latent force fm to each output gq(t). Through this
formulation, one can recover the latent force functions fm(t) and the output functions gq(t) from
discrete observations. Solving the ODE yields
gq(t) =
Bq
Dq
+
M∑
m=1
Sqm exp(−Dqt)
∫ t
0
fm(τ) exp(Dqτ)dτ. (4)
In LFMs, the latent forces fm are modeled independently as samples from their respective GPs. For
certain classes of covariance functions, such as SE kernels, one can show that the outputs gq are also
GPs with analytically closed-form covariance functions, as well as cross-covariances between latent
forces and the outputs (Alvarez et al., 2009).
While sampling the latent forces fm from independent GPs is computationally convenient, impor-
tant information can be lost. For example, when provided with historical patient data, we might
want to know how latent physiological dynamics are shared across patients from related covariate
groups (i.e., same age, sex, BMI) or across patients receiving similar treatments. Limited numbers
of observations also motivates a hierarchical approach to this problem, in order to share strength
across patients.
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2.3 Treatment Effect Estimation
In addition to modeling physiological outputs, accurate modeling of medical data sets requires incor-
porating various treatment effects, with the purpose of controlling or stabilizing the physiological
states of patients. Treatments are often drug interventions that can be characterized by drug name,
administration type (e.g., oral, intravenous), and dosage. Estimating the effect of a treatment on a
patient’s physiological state is paramount to improving prediction and evaluating treatments.
While GPs are commonly used to model medical time series data, several extensions have been
proposed to estimate the effects of medical treatments. Counterfactual Gaussian processes (CGPs)
(Schulam and Saria, 2017) use marked point processes (MPP) as an event model to account for
dependencies between actions and observed physiological trajectories. In Xu et al. (2016), a class
of parametric functions is introduced to model the effects of dialysis for patients with acute kidney
injury. The functions were designed to explicitly model different types of effects, including delay
and decay. To explain heterogeneity across patients, a Dirichlet process was used for clustering
patients. In Futoma et al. (2017), the treatment effects are modeled in the prior mean function of
multi-output Gaussian processes, formulated as the sum of multiple exponential decay functions.
These approaches require the response dynamics to conform to a specific functional form such as
exponential decay, where in practice they are much more heterogeneous.
More recently, Soleimani et al. (2017) introduces treatment effects as the output of a linear time-
invariant (LTI) system. The inputs are the observed administration of medications (e.g., type and
dosage), and the effects are estimated based on a chosen form of a second-order filter. Patient-
specific filter parameters were estimated and regularized using a global prior across patients.
To allow the treatment response to take on arbitrary functional forms with scalable effects sizes
and directions, we use a hierarchical GP to model the latent forces. In particular, we replace the
independent GPs with a causal-kernel GP whose hyperparameters are shared across patients to allow
arbitrary functional response and to share strength by representing correlations across patient groups.
3 Causal Convolutional Gaussian Processes
Here, we propose a flexible framework to model medical time series data. Our method brings
together ideas from GP latent force models (Alvarez et al., 2009; Särkkä et al., 2017) and causal
GPs (Cunningham et al., 2012) to address a challenge in modeling medical time series data—the
systematic inclusion of multi-treatment effects on the dynamics of multiple physiological covariates.
We first introduce the notation in the context of medical time series data, and then introduce the
model. We also discuss the details of implementation and inference methods.
3.1 Medical Time Series with Treatments
We denote the observed medical time series data yi,j(t) from i = {1, 2, . . . , n} patients character-
ized by j = {1, 2, . . . , J} physiological dynamic covariates across irregularly sampled time points
t = {1, 2, . . . , Ti,j}, as noisy samples from a Gaussian process with a patient- and covariate-specific
mean function µi,j(t) and kernel kbi,j(t, t
′):
yi,j(t) = fi,j(t) + ǫj , ǫj ∼ N (0, σ2i,j)
fi,j(t) ∼ GP
(
µi,j(t), k
b
i,j(t, t
′)
)
. (5)
Here, the kernel kbi,j accounts for stationary temporal fluctuations of physiological signals, such as
circadian rhythms. We choose this kernel as a sum of one SE kernel and one periodic kernel:
kbi,j = kSE + kPER = σ
2
1,i,j exp
[
− (t− t
′)2
2ℓ2
1,i,j
]
+ σ2
2,i,j exp
[
− sin
2 (π||t−t
′||/pi,j)
2ℓ2
2,i,j
]
. (6)
For each patient i, we index treatments given asm = 1, 2, . . . ,Mi, and the time of treatments is de-
noted as ti
1
, ti
2
, . . . tiMi . For each treatment, we use function τi : 1, 2, . . . ,Mi → T to map the index
of the treatment to a treatment set T representing the type of treatment. Since the dosage-response
curve of the same drug usually has a nonlinear curve that varies across dosages (Myers and Thiessen,
1980; Ghassemi et al., 2014), and the characteristics of absorption vary across different routes, we
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treat the same drug with different dosages or taken via different routes (e.g., oral or injection) as dif-
ferent treatments. Whenever clear from the context, we drop the patient index from these variables.
We assume there are different latent forces induced by each type of treatment. For a treatment m
given at time tm, we model the latent force as a function of time fm(t; tm) drawn from a Gaussian
process. We also assume that each patient has a patient-specific latent force, and use a hierarchical
model to share support for latent force models across patients.
3.2 Causal Treatment Dynamics
The dynamic behavior of a treatment’s response to the clinical covariates are represented in our
setup as a latent force model. In particular, we model the mean function µi,j(t) of the clinical traits
through the first-order dynamical system LFM:
dµi,j(t)
dt
+Di,jµi,j(t) = Bi,j +
Mi∑
m=1
Si,j,mfm(t; tm), (7)
where the decayDi,j , the baseline covariate outputBi,j , and treatment effect size Si,j,m are patient-
specific parameters that control the dynamics of the treatment response. We assume these patient-
specific parameters come from a population-wise empirical prior based on demographic data, such
as age and weight. We assume the latent force function fm(t; tm) of the same treatment is shared
across patients, and is sampled from a Gaussian process:
fm(t; tm) ∼ GP(0, kf,f ′(t, t′; tm)). (8)
We introduce causality on the latent force functions associated with each treatment, which means
that causal effects must only act forward in time. To do this, we designed the kernel kf,f ′(t, t′; tm)
as a causal kernel (Cunningham et al., 2012). That is,
kf,f ′(t, t
′; tm) = exp
{
− [h(t− tm)− h(t
′ − tm)]2
ℓ2m
}
, (9)
where h(t) = tI(t > 0) is the clipping function warping the input space and enforcing causality,
while preserving the GP structure (Cunningham et al., 2012). Through h(t), the function fm(t; tm)
is constant before the current time tm. In our model of treatment effects, we introduce an additional
condition fm(t; tm) = 0 for t < tm.
3.3 Kernel Convolution
The structure of the latent force model leads to a natural composition with the causal Gaussian
process prior, leading to an analytic computation of output covariances and cross-covariances. This
fact allows for simple gradient descent-based inference. Closed-form kernels were derived following
the integral in Eqn. 4. For instance, the cross-covariance between µi,j(t) and one latent force fm(t)
when t, t′ > tm is computed as
kµi,j ,fm(t, t
′; tm) = Si,j,m exp (−Di,jt) exp
[
−
(
t′ − tm
ℓm
)2]
× 1
Di,j
[exp (Di,jtm)− 1]
+
√
πℓ
2
Si,j,m exp [−Di,j(t− t′)] exp (ν2i,j,m)×
[
erf
(
t− t′
ℓm
− νi,j,m
)
+ erf
(
t′ − tm
ℓm
+ νi,j,m
)]
,
(10)
where νi,j,m =
ℓmDi,j
2
. Details of the computation of the closed-form kernels corresponding to the
cases t > tm > t′, tm > t, t′, and t′ > tm > t are in the Supplementary Material.
3.4 Hyperparameter Learning for Medication Effects Model
To learn the hyperparameters for each patient, we optimize the marginal likelihood of the GP model
with respect to the vector of observations across covariates xi and yi.
log p(yi|xi, θ) = − 12 (yi − µi)⊤(Ki|θ + ǫI)−1(yi − µi)
− 1
2
log |Ki|θ + ǫI| −
(∑J
j=1
Ti,j
2
)
log (2π),
(11)
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Antihypertensive Agents (N = 181) Count
Heart Rate (HR) 9,798
Systolic Blood Pressure (SBP) 7,804
Metoprolol Tartrate (6.25 mg) 42
Metoprolol Tartrate (12.5 mg) 92
Metoprolol Tartrate (25 mg) 93
Metoprolol Tartrate (50 mg) 40
Metoprolol Succinate ER (25 mg) 22
Metoprolol Injection (5 mg) 21
Anticoagulants (N = 404) Count
Partial Thromboplastin Time (PTT) 4,911
International Normalized Ratio (INR) 4,348
Heparin Injection (5000 units) 246
Heparin Infusion (25000 units) 319
Warfarin (5mg) 27
Table 1: Data statistics of the two drug types used in the experiments. Total number of observa-
tions for the targeted vital signs and lab results, and the count of targeted treatments.
where µi = µi,j(xi). For each patient, we learn a set of hyperparameters θ for the baseline kernel
for each covariate {σ1,i,j , ℓ1,i,j , σ2,i,j , ℓ2,i,j, pi,j}, and the hyperparameters of the derived causal
LFM kernel, with the mean function sampled from {Bi,j , Di,j, Si,j,m, ℓi,j,m}. We assume that
the patient- and treatment-specific hyperparameters are shared across treatments of the same type,
while the treatment effect size parameter differs for different dosages or modes of administration.
Our implementation is based on GPy (GPy, 2012), and we optimize the hyperparameters using scale
conjugate gradient methods. We derived the gradients using the SymPy package (Meurer et al.,
2017).
4 Experiments
In this section, we show the effectiveness of our method by modeling multiple treatment effects
on EHR data from the Hospital of University of Pennsylvania (HUP). We briefly describe the data
and preprocessing procedures, and then we discuss results from our method fitted to patient subsets
motivated by two clinical applications. We show empirical results of our method using the metrics
of prediction accuracy. We compare results with baseline methods with GPs using basic kernels and
mean functions from related work (Futoma et al., 2017; Soleimani et al., 2017).
4.1 Inpatient Hospital Data
We evaluated our method using clinical data collected at HUP. The data set consists of 139k patients
with access to demographic details (e.g., age, weight, gender), as well as 139 clinical measurements
consisting of vital signs and lab tests, and administrated medications during the patients’ stay in the
hospital. We normalized each clinical trait by subtracting the empirical mean for each patient from
each measurement. We tested our method on two challenging applications—modeling the effects
of antihypertensive agents and anticoagulants. We chose to focus on the patients with a primary
diagnosis of myocardial infarction (MI; i.e., heart attack) in our data set, resulting in total 1,716
adult patients, as they usually received both types of treatments.
We first modeled the effects of the most frequently administered antihypertensive drug in our data set,
metoprolol, on heart rate (HR) and systolic blood pressure (SBP). Metoprolols are beta-blockers that
are mainly used to treat high blood pressure or angina due to heart disease. We filtered MI patients
to include patients with at least five observations in both heart rate or blood pressure, reducing
the number of patients to 594. We removed patients that were administrated metropolol jointly
with other antihypertensive agents, resulting in 233 patients. Finally, we included treatments of
metoprolol that were administered at least 20 times across all patients, resulting in 181 patients with
six type of treatments, including four different dosages of metoprolol tartrate, and one dosage for
metoprolol succinate ER and metoprolol injection, and a total of 310 treatment administrations.
Second, we modeled the effect of two different types of anticoagulants: heparin and warfarin. We
filtered the MI patients to include those with at least five observations on two lab test results that
reflect a patient’s ability to form blood clots: partial thromboplastin time (PTT) and international
normalized ratio (INR), resulting in 581 patients. Among all treatments, we considered the top three
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Covariate Antihypertensive Agents
SE+PER OU+EXP MAT32+LTI Proposed
SBP 10.688± 0.242 11.547± 0.292 10.502± 0.240 10.882± 0.242
HR 7.694± 0.173 7.780± 0.186 7.791± 0.173 7.851± 0.179
Covariate
Anticoagulants
SE+PER OU+EXP MAT32+LTI Proposed
PTT 12.646± 0.379 12.431± 0.512 12.436± 0.376 12.248± 0.368
INR 0.204± 0.009 0.339± 0.013 0.596± 0.011 0.180± 0.009
Table 2: Prediction results on test data. MAE (± standard error) were computed for results from
our method and three comparison methods using univariate GPs with different mean functions and
kernels. Our method performs competitively across covariates under the treatments of antihyperten-
sive agents and better than the comparison methods under the treatments of anticoagulants.
HR
SBP
Latent Force
Time (hours) Time (hours)
(a) (b)
(e)
Time (hours)
Time (hours) Time (hours)
(c) (d)
metoprolol tartrate - 50 mg (train)
metoprolol tartrate - 50 mg (test)
GP posterior meanGP prior mean
GP posterior 95% CIobservations (test)
observations (train)
Normal Range
SB
P
SB
P
H
R
H
R
Figure 1: Prediction of systolic blood pressure (SBP) and heart rate (HR) for one patient under
metroprolol tartrate treatments. (a) and (b): results from a related method MAT32+LTI. (c) and
(d): results from the proposed method. (e) The learned latent force for the first metroprolol tartrate
(50 mg) treatment and the effects on SBP and HR; the recovered effects on SBP and HR are in their
original units. Our method achieves higher confidence (lower variance) and greater consistency with
known clinical effects than the related model.
most frequently administered, and we include patients that received at least one of them. The filtered
data includes 404 patients with a total of 592 treatment administrations (Table 1).
4.2 Evaluation Metrics
We evaluated our model by comparing predictive performancewith three state-of-the-art GP models:
(i) univariate GPs with a constant mean function and the baseline (squared exponential and periodic)
kernel kbi,j(t, t
′) (Eqn. 6; SE+PER), (ii) univariate GPs with an exponential decay mean function and
the Ornstein-Uhlenbeck (OU) kernel (Futoma et al., 2017) (OU+EXP), and (iii) Mate´rn-3/2 kernel
with a second-order LTI filter for effect modeling (Soleimani et al., 2017) (MAT32+LTI). Note that
for the comparative method (ii) and (iii), we added a constant component in the mean function in
the proposed setup to account for patient-specific baseline values of each covariate. For all methods,
we used the first 70% of observations for each patient for training, and the remaining 30% for
testing. We computed the mean absolute error (MAE) of predictions on test data to evaluate model
performance.
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Time (hours) Time (hours)
(a) (b)
(e)
Time (hours)
Time (hours) Time (hours)
(c) (d)
heparin infusion 25000 units (train)GP posterior meanGP prior mean
GP posterior 95% CIobservations (test)
observations (train)
Normal Range
PT
T
PT
T
IN
R
IN
R
PTT
INR
Latent Force
heparin injection 5000 units (train)
heparin injection 5000 units (test)
PTT
INR
Latent Force
(f)
Time (hours)
Figure 2: Prediction of partial thromboplastin time (PTT) and international normalized ratio
(INR) for one patient under heparin treatments. (a) and (b): results from the related method
MAT32+LTI. (c) and (d): results from the proposed method. (e) and (f): the estimated latent force
for one heparin infusion (25000 units) and one heparin injection (5000 units), and their effects on
PTT and INR; the recovered effects on PTT and INR are in their normalized units.
4.3 Clinical Impact
When comparing the MAE on test data for the two experiments (antihypertensive agents and antico-
agulants; Table 2), our method performed competitively across experiments on the predictive tasks
for the covariates responding to antihypertensives. Our model performs better than related methods
on the task of predicting traits responding to anticoagulants, in particular the blood clot formation
trait PTT.
While predictive performance is similar across related methods, our method shows important advan-
tages in model flexibility. We demonstrate this through two case studies: First, we study predictive
trajectories and the inferred effects on blood pressure and heart rate of a treatment on one patient
(Fig. 1). The patient received 50 mg of metoprolol tartrate . We compare the predictive trajectory
with uncertainty from a related method (Mat32+LTI) (Fig. 1 a–b) with results from our method
(Fig. 1 c–d). Our method estimates an explicit treatment-induced latent force with strong effects
on both heart rate and systolic blood pressure (Fig. 1 e) that matches the time frame prescribed by
clinical medicine. Indeed, the direction of estimated effects from the related method on SBP (Fig. 1
a and b) is the opposite of the clinical usage; this error may be due to delayed effect of the drug on
SBP. While for this patient the MAE of the related method is slightly lower than our method (4.68
vs. 5.37 in SBP; 7.90 vs. 8.09 in HR), results from our method are closer to clinical ground truth
with substantially lower uncertainty. Furthermore, with the GP model of latent force, our estimated
effect is more robust than a standard latent force model when presented with additional uncertainty
and noise in the data, such as delayed effects from the time of treatment administration, which is
important in the clinical setting.
Next, we find similar robust and clinically interpretable behavior are achieved for a patient receiving
multiple heparin infusions (25000 units) and heparin injections (5000 units; Fig. 2). For both our
method and the related method (MAT32+LTI), the longer-term effects on PTT is estimated (Fig. 2,
a and c). Both methods estimated negative effects for the heparin injections (Fig. 2 f), while in
general heparin is assumed not to affect INR (Katzung and Trevor, 2015).
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5 Discussion
We developed a framework using latent force models (LFMs) to capture treatment effects on pa-
tients’ physiological state estimated using medical time series data. By modeling treatment effects
as latent forces convolved with a multi-output GP, we create a flexible framework that bridges the
gap between the smooth, stationary dynamics of patient state and a mechanistic understanding of the
forces that impact clinical traits. A GP model of latent forces provides a flexible probabilistic frame-
work with convenient inference properties; we enforce appropriate effect dynamics using a causal
kernel. Two key contributions, the latent force model convolution and the associated causal kernel,
lead to a computationally tractable solution with low variance and clinically-relevant interpretation
of personalized treatment effects. Further improvements in speed may be found by adapting a recent
kernel approximation (Guarnizo and Lopez, 2018).
There are several directions to improve our method for clinical treatment effect estimation. Our
framework assumes that the effect of each treatment is independent of any other, and interactions
between treatments are not modeled. These interactions could be modeled by modifying the kernel
for the latent force component. In addition, the method assumes the decay parameters (Di,j) of the
treatment effect for a single patient are treatment-independent and constant throughout the patient’s
hospital stay. As the decay parameters reflect the physiology of drug absorption, which may change
as a function of patient state, we might model this parameter as a stochastic process itself. For future
research, the latent force model encourages an optimal control perspective: estimating treatment
effect sizes of each patient for each clinical covariate, coupled with accurate patient state prediction,
can provide a path toward treatment prioritization and decision-making in clinical interventions.
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